Silvia Novello
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080317_silvia_novello.mp3]